Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

34 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Visceral Leishmaniasis in 2 Patients Treated With Lenalidomide and Dexamethasone: A Possible Correlation With Blunted Immune Response.
Hadjiaggelidou C, Vadikolia C, Verrou E, Yiannaki E, Triantafyllou T, Palaska V, Keramidioti K, Tsirou K, Papanikolaou A, Markala D, Konstantinidou P, Katodritou E. Hadjiaggelidou C, et al. Among authors: konstantinidou p. Hemasphere. 2020 Dec 9;5(1):e506. doi: 10.1097/HS9.0000000000000506. eCollection 2021 Jan. Hemasphere. 2020. PMID: 33324952 Free PMC article. No abstract available.
Evaluation of regulatory T cells (Tregs) alterations in patients with multiple myeloma treated with bortezomib or lenalidomide plus dexamethasone: correlations with treatment outcome.
Hadjiaggelidou C, Mandala E, Terpos E, Yiannaki E, Markala D, Triantafyllou T, Papatheodorou A, Gkastari V, Verrou E, Papanikolaou A, Konstantinidou P, Katodritou E. Hadjiaggelidou C, et al. Among authors: konstantinidou p. Ann Hematol. 2019 Jun;98(6):1457-1466. doi: 10.1007/s00277-019-03657-3. Epub 2019 Mar 20. Ann Hematol. 2019. PMID: 30895351
A proposed index of diffuse bone marrow [18F]-FDG uptake and PET skeletal patterns correlate with myeloma prognostic markers, plasma cell morphology, and response to therapy.
Paschali A, Panagiotidis E, Triantafyllou T, Palaska V, Tsirou K, Verrou E, Υiannaki E, Markala D, Papanikolaou A, Pouli A, Konstantinidou P, Chatzipavlidou V, Terpos E, Katodritou E. Paschali A, et al. Among authors: konstantinidou p. Eur J Nucl Med Mol Imaging. 2021 May;48(5):1487-1497. doi: 10.1007/s00259-020-05078-1. Epub 2020 Oct 25. Eur J Nucl Med Mol Imaging. 2021. PMID: 33099659
Real-world data on incidence, clinical characteristics and outcome of patients with macrofocal multiple myeloma (MFMM) in the era of novel therapies: A study of the Greco-Israeli collaborative myeloma working group.
Katodritou E, Kastritis E, Gatt M, Cohen YC, Avivi I, Pouli A, Lalayianni C, Lavi N, Delimpasis S, Kyrtsonis MC, Michael M, Suriu C, Miri Z, Tzafarti K, Vadikoliou C, Maltezas D, Zikos P, Ganzel C, Vaxman Y, Aviv A, Christoforidou A, Gavriatopoulou M, Shaulov A, Verrou E, Papanota AM, Fakinos G, Gkioka AI, Palaska V, Triantafyllou T, Konstantinidou P, Anagnostopoulos A, Terpos E, Dimopoulos MA. Katodritou E, et al. Among authors: konstantinidou p. Am J Hematol. 2020 May;95(5):465-471. doi: 10.1002/ajh.25755. Epub 2020 Mar 2. Am J Hematol. 2020. PMID: 32048329 Free article.
Is it possible to cure myeloma without allogeneic transplantation?
Katodritou E, Papadaki S, Konstantinidou P, Terpos E. Katodritou E, et al. Among authors: konstantinidou p. Transfus Apher Sci. 2016 Feb;54(1):63-70. doi: 10.1016/j.transci.2016.01.015. Epub 2016 Jan 21. Transfus Apher Sci. 2016. PMID: 26850930 Review.
Real-world data on prognosis and outcome of primary plasma cell leukemia in the era of novel agents: a multicenter national study by the Greek Myeloma Study Group.
Katodritou E, Terpos E, Delimpasi S, Kotsopoulou M, Michalis E, Vadikolia C, Kyrtsonis MC, Symeonidis A, Giannakoulas N, Vadikolia C, Michael M, Kalpadakis C, Gougopoulou T, Prokopiou C, Kaiafa G, Christoulas D, Gavriatopoulou M, Giannopoulou E, Labropoulou V, Verrou E, Kastritis E, Konstantinidou P, Anagnostopoulos A, Dimopoulos MA. Katodritou E, et al. Among authors: konstantinidou p. Blood Cancer J. 2018 Mar 9;8(3):31. doi: 10.1038/s41408-018-0059-6. Blood Cancer J. 2018. PMID: 29523783 Free PMC article. Clinical Trial.
Clinical features, outcome, and prognostic factors for survival and evolution to multiple myeloma of solitary plasmacytomas: a report of the Greek myeloma study group in 97 patients.
Katodritou E, Terpos E, Symeonidis AS, Pouli A, Kelaidi C, Kyrtsonis MC, Kotsopoulou M, Delimpasi S, Christoforidou A, Giannakoulas N, Viniou NA, Stefanoudaki E, Hadjiaggelidou C, Christoulas D, Verrou E, Gastari V, Papadaki S, Polychronidou G, Papadopoulou A, Giannopoulou E, Kastritis E, Kouraklis A, Konstantinidou P, Anagnostopoulos A, Zervas K, Dimopoulos MA. Katodritou E, et al. Among authors: konstantinidou p. Am J Hematol. 2014 Aug;89(8):803-8. doi: 10.1002/ajh.23745. Epub 2014 May 12. Am J Hematol. 2014. PMID: 24757085 Free article.
Lack of survival improvement with novel anti-myeloma agents for patients with multiple myeloma and central nervous system involvement: the Greek Myeloma Study Group experience.
Katodritou E, Terpos E, Kastritis E, Delimpasis S, Symeonidis AS, Repousis P, Kyrtsonis MC, Vadikolia C, Michalis E, Polychronidou G, Michael M, Papadaki S, Papathanasiou M, Kokoviadou K, Kioumi A, Vlachaki E, Hadjiaggelidou C, Kouraklis A, Patsias I, Gavriatopoulou M, Kotsopoulou M, Verrou E, Gastari V, Christoulas D, Giannopoulou E, Pouli A, Konstantinidou P, Anagnostopoulos A, Dimopoulos MA. Katodritou E, et al. Among authors: konstantinidou p. Ann Hematol. 2015 Dec;94(12):2033-42. doi: 10.1007/s00277-015-2484-y. Epub 2015 Sep 30. Ann Hematol. 2015. PMID: 26420061 Clinical Trial.
34 results